A marijuana multi-state operator (MSO) that was part of the largest public launch on an emerging Canadian exchange has announced a study to determine the potential of medical cannabis in treating patients with inflammatory arthritis.

On Tuesday (May 21), Columbia Care (NEO:CCHW) confirmed a collaborative medical study with Westmed Medical Group to inspect the effectiveness of treatment using its ClaraCeed cannabidiol (CBD) tablets for pain management.

Nearly 100 patients will be examined for six months using these tablets alongside any current non-opioid-based treatments the patients may already use.

Rosemary Mazanet, chief scientific officer and chair of the scientific advisory board at Columbia Care, said the company sees this study as the first to look at a treatment option for rheumatologic patients.

She added that the company has seen anecdotal findings from patients with cannabis-based medicines, but hopes the new study will help confirm the validity of these claims with the ClaraCeed tablets.

As part of the study, enrolled patients will be monitored with a monthly check in from the researchers, including the collection of a patient global assessment, a patient reported outcomes estimate and a pain score based on the results from the medicine combination.

“We are also collecting safety information regarding the use of medical cannabis in the rheumatologic population, many of whom are taking numerous other medications,” Dr. Jill Landis, board certified rheumatologist at Westmed and lead on the study, said in a press release.

Shares of Columbia Care were down in Wednesday’s (May 22) trading session by 2.67 percent as of 3:19 p.m. EDT, indicating a price point of C$8.75.

As part of its first quarterly update since going public, the firm reported revenue of US$12.9 million.

“Access to the public capital markets will allow us to accelerate growth as we expand operations in 12 of our 14 existing jurisdictions and enable us to expedite the commercialization of our hemp-based CBD brands into traditional consumer retail channels,” said Nicholas Vita, CEO of the company.

Following its public debut, the firm was quickly added to a new US cannabis exchange-traded fund (ETF) from Horizons ETFs Management (Canada).

The inclusion of Columbia Care into the Horizons US Marijuana Index ETF (NEO:HMUS) was done by way of a special “fast entry” rule from the fund operators, as the norm for new stocks is to be added during a quarterly rebalancing of the fund.

Horizons ETFs describes the rule as an option “to add new stocks into the portfolio shortly after they become publicly available, assuming they qualify for index inclusion.”

Columbia Care’s valuation granted it a maximum weighting of 10 percent among the fund’s total holdings. As of Tuesday, Columbia Care was the third stock by weight in the fund at 10.22 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its wholly owned subsidiary, Probulin Probiotics, LLC (“ Probulin ”), has increased its product selection in certain brick and mortar locations and expanded its distribution on Amazon through a unique eCommerce store within the Amazon platform. The broader product selection is available in major brick and mortar stores including Sprouts and Fresh Thyme and includes the Company’s new Probulin Total Care Immune product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005411/en/

Keep reading... Show less

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/72301_betterplanta.jpg

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE: CSI) (OTC: CADMF) (FRA: CWAA) is pleased to announce that all matters submitted to the shareholders of the Company at the Annual General and Special Meeting of the Company’s shareholders held on December 31, 2020 were approved.
In addition, the Company has granted, pursuant to its Equity Incentive Plan, options to purchase 1,500,000 shares of the Company exercisable for a period of 5 years at USD$0.70 per share to the directors, officers and consultants of the Company. The Company has also granted, pursuant to its Equity Incentive Plan, restricted share rights to acquire 1,500,000 shares of the Company to the directors, officers and consultants of the Company. One-half of such restricted share rights shall vest in three months from the grant date and the remaining one-half shall vest in six months from the grant date.
On Behalf of The Board of Directors
Josh Rosenberg
Investor Relations:
1 (604) 398-3378
The CSE has not reviewed, approved or disapproved the content of this press release


Keep reading... Show less